Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-dense high-dose methotrexate plus radiotherapy for primary central nervous system lymphoma
ChiCTR-OIC-17011982Phase 2Not yet recruiting
- Sponsor
- Cancer Center, Renmin Hospital of Wuhan University
- Start
- Aug 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate in primary central nervous system lymphoma (PCNSL), sponsored by Cancer Center, Renmin Hospital of Wuhan University. Primary endpoints: complete response, partial response and 3 more. Planned start Aug 2017; status: not yet recruiting.
02
Drugs
methotrexate
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on ChiCTR-OIC-17011982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17011982.